Researchers have established what they believe to be a clinically relevant threshold for the serum neurofilament light chain (sNfL) test, paving the way for its future implementation in routine practice.
The test is widely used in clinical trials and has been shown to be linked to disease activity, predicting long-term clinical and imaging outcomes. Levels of SNfL have also been shown to be reduced by the use of disease-modifying therapies.
The test measures serum levels of neurofilaments that are released after axonal damage.
At ECTRIMS, Dr Peter Calabresi of Johns Hopkins Hospital in Baltimore, Maryland, USA, presented data from a study assessing the SIMOA assay for sNfL. The study collected data from four clinical trials, involving more than 1,000 patients with relapsing-remitting MS.